by MM360 Staff | Jul 16, 2025 | Uncategorized
Source: CureToday articles The program emphasized the importance of incorporating patient and caregiver perspectives alongside clinical expertise to support personalized, empathetic care and shared decision-making in managing the diverse and complex challenges of...
by MM360 Staff | Jul 16, 2025 | Uncategorized
Source: CureToday articles Panelists discuss the multifaceted diagnostic process for multiple myeloma, emphasizing the integration of blood tests, genetic and imaging assessments, and patient education to guide personalized treatment planning and enhance patient...
by Josh Friedman | Jul 7, 2025 | Uncategorized
Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis of individuals diagnosed with multiple myeloma showed that those who reported having “low” physical function, such as struggling to do...
by MM360 Staff | Jul 3, 2025 | Uncategorized
Source: CureToday articles The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program. Read More
by Lucas Laboy | Jul 2, 2025 | Uncategorized
The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome...
by MM360 Staff | Jun 27, 2025 | Uncategorized
Source: CureToday articles Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting. Read More
